Survival outcomes with 12 weeks of adjuvant or neoadjuvant trastuzumab in breast cancer

Simple item page
dc.contributor.authorGhosh, Joydeepen_US
dc.contributor.authorPhillip, Deepa S Joyen_US
dc.contributor.authorGhosh, Jayaen_US
dc.contributor.authorBajpai, Jyotien_US
dc.contributor.authorGulia, Seemaen_US
dc.contributor.authorParmar, Vanien_US
dc.contributor.authorNair, Nitaen_US
dc.contributor.authorJoshi, Shalakaen_US
dc.contributor.authorSarin, Rajiven_US
dc.contributor.authorBudrukkar, Ashwini Nen_US
dc.contributor.authorWadasadawala, Tabassumen_US
dc.contributor.authorDesai, Sangeeta Ben_US
dc.contributor.authorShet, Tanujaen_US
dc.contributor.authorPatil, Asawarien_US
dc.contributor.authorSawant, Sheela Pen_US
dc.contributor.authorDhir, Aruna Aen_US
dc.contributor.authorKembhavi, Seemaen_US
dc.contributor.authorPopat, Palaken_US
dc.contributor.authorHawaldar, Rohinien_US
dc.contributor.authorKembhavi, Yogeshen_US
dc.contributor.authorPerumal, Premaen_US
dc.contributor.authorBanavali, Shripad Den_US
dc.contributor.authorBadwe, Rajendra Aen_US
dc.contributor.authorGupta, Sudeepen_US
dc.date.accessioned2023-08-09T06:04:09Z
dc.date.available2023-08-09T06:04:09Z
dc.date.issued2022-09
dc.description.abstractBackground: There is limited access to 1 year of adjuvant trastuzumab in resource-constrained settings. Most randomized studies have failed to prove non-inferiority of shorter durations of adjuvant trastuzumab compared to 1 year However, shorter durations are often used when 1 year is not financially viable. We report the outcomes with 12 weeks of trastuzumab administered as part of curative-intent treatment. Methods: This is a retrospective analysis of patients treated at Tata Memorial Centre, Mumbai, a tertiary care cancer center in India. Patients with human epidermal growth factor receptor (HER2)-positive early or locally advanced breast cancer who received 12 weeks of adjuvant or neoadjuvant trastuzumab with paclitaxel and four cycles of an anthracycline-based regimen in either sequence, through a patient assistance program between January 2011 and December 2012, were analyzed for disease-free survival (DFS), overall survival (OS), and toxicity. Results: A total of 102 patients were analyzed with a data cutoff in September 2019. The median follow-up was 72 months (range 6–90 months), the median age was 46 (24–65) years, 51 (50%) were postmenopausal, 37 (36%) were hormone receptor-positive, and 61 (60%) had stage-III disease. There were 37 DFS events and 26 had OS events. The 5-year DFS was 66% (95% Confidence Interval [CI] 56–75%) and the OS was 76% (95% CI 67–85%), respectively. Cardiac dysfunction developed in 11 (10.7%) patients. Conclusion: The use of neoadjuvant or adjuvant 12-week trastuzumab-paclitaxel in sequence with four anthracycline-based regimens resulted in acceptable long-term outcomes in a group of patients, most of whom had advanced-stage nonmetastatic breast cancer.en_US
dc.identifier.affiliationsDepartments of Medical Oncologyen_US
dc.identifier.affiliationsSurgical Oncologyen_US
dc.identifier.affiliationsRadiation Oncologyen_US
dc.identifier.affiliationsPathologyen_US
dc.identifier.affiliationsGeneral Medicine anden_US
dc.identifier.affiliationsRadiodiagnosisen_US
dc.identifier.affiliationsTMC Research Administration Councilen_US
dc.identifier.affiliationsResearch Project Manageren_US
dc.identifier.affiliationsResearch Fellow, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, Indiaen_US
dc.identifier.citationGhosh Joydeep, Phillip Deepa S Joy, Ghosh Jaya, Bajpai Jyoti, Gulia Seema, Parmar Vani, Nair Nita, Joshi Shalaka, Sarin Rajiv, Budrukkar Ashwini N, Wadasadawala Tabassum, Desai Sangeeta B, Shet Tanuja, Patil Asawari, Sawant Sheela P, Dhir Aruna A, Kembhavi Seema, Popat Palak, Hawaldar Rohini, Kembhavi Yogesh, Perumal Prema, Banavali Shripad D, Badwe Rajendra A, Gupta Sudeep. Survival outcomes with 12 weeks of adjuvant or neoadjuvant trastuzumab in breast cancer. Indian Journal of Cancer . 2022 Sep; 59(3): 387-393en_US
dc.identifier.issn0019-509X
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/221705
dc.languageenen_US
dc.publisherWolters Kluwer - Medknowen_US
dc.relation.issuenumber3en_US
dc.relation.volume59en_US
dc.source.urihttps://doi.org/10.4103/ijc.IJC_850_19en_US
dc.subjectAdjuvanten_US
dc.subjectneoadjuvanten_US
dc.subjectresource constraineden_US
dc.subjectshort courseen_US
dc.subjecttrastuzumab breasten_US
dc.titleSurvival outcomes with 12 weeks of adjuvant or neoadjuvant trastuzumab in breast canceren_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJC2022v59n3p387.pdf
Size:
516.89 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Cancer